Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Kramar

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Bulletin Du Cancer|December 26, 2008
[Role of the methodology in cluster randomized trials]Andrew Kramar, Franck Bonnetain, Simone Mathoulin-Pélissier
Critical Reviews in Oncology/Hematology|May 28, 2013
Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survivalNicolas Penel, Sophie Cousin, Alain Duhamel, et al.
Bulletin Du Cancer|January 7, 2004
[Increasing the quality of clinical trials in oncology: an important challenge]Andrew Kramar, Taras Kachmar, Jean-Michel Hannoun-Lévi
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 11, 2009
Planning posttherapeutic oncology surveillance visits based on individual riskT Filleron, A Barrett, O Ataman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2005
Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTROOzlem Uruk Ataman, Ann Barrett, Thomas Filleron, et al.
Computer Methods and Programs in Biomedicine|March 27, 2010
An R function to non-parametric and piecewise analysis of competing risks survival dataThomas Filleron, Agnès Laplanche, Jean-Marie Boher, et al.
Statistics in Medicine|March 11, 2003
Two-treatment comparison based on joint toxicity and efficacy ordered alternatives in cancer trialsAlexia Letierce, Pascale Tubert-Bitter, Andrew Kramar, et al.
Journal of Biopharmaceutical Statistics|February 11, 2005
A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approachPascale Tubert-Bitter, Alexia Letierce, Daniel A Bloch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Survival end point reporting in randomized cancer clinical trials: a review of major journalsSimone Mathoulin-Pelissier, Sophie Gourgou-Bourgade, Franck Bonnetain, et al.
The Breast Journal|March 6, 2013
Breast imaging: understanding how accuracy is measured when lesion are the unit of analysisThomas Filleron, Florence Dalenc, Frédéric Courbon, et al.
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Bulletin Du Cancer|December 26, 2008
[Role of the methodology in cluster randomized trials]Andrew Kramar, Franck Bonnetain, Simone Mathoulin-Pélissier
Critical Reviews in Oncology/Hematology|May 28, 2013
Activity endpoints reported in soft tissue sarcoma phase II trials: quality of reported endpoints and correlation with overall survivalNicolas Penel, Sophie Cousin, Alain Duhamel, et al.
Bulletin Du Cancer|January 7, 2004
[Increasing the quality of clinical trials in oncology: an important challenge]Andrew Kramar, Taras Kachmar, Jean-Michel Hannoun-Lévi
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 11, 2009
Planning posttherapeutic oncology surveillance visits based on individual riskT Filleron, A Barrett, O Ataman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 1, 2005
Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTROOzlem Uruk Ataman, Ann Barrett, Thomas Filleron, et al.
Computer Methods and Programs in Biomedicine|March 27, 2010
An R function to non-parametric and piecewise analysis of competing risks survival dataThomas Filleron, Agnès Laplanche, Jean-Marie Boher, et al.
Statistics in Medicine|March 11, 2003
Two-treatment comparison based on joint toxicity and efficacy ordered alternatives in cancer trialsAlexia Letierce, Pascale Tubert-Bitter, Andrew Kramar, et al.
Journal of Biopharmaceutical Statistics|February 11, 2005
A nonparametric comparison of the effectiveness of treatments: a multivariate toxicity-penalized approachPascale Tubert-Bitter, Alexia Letierce, Daniel A Bloch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2008
Survival end point reporting in randomized cancer clinical trials: a review of major journalsSimone Mathoulin-Pelissier, Sophie Gourgou-Bourgade, Franck Bonnetain, et al.
The Breast Journal|March 6, 2013
Breast imaging: understanding how accuracy is measured when lesion are the unit of analysisThomas Filleron, Florence Dalenc, Frédéric Courbon, et al.
Pageof 9